Inmed Pharmaceuticals Stock Probability Of Bankruptcy
InMed Pharmaceuticals' likelihood of distress is above 80% at the present time. It has very high risk of going through financial hardship in the upcoming years. InMed Pharmaceuticals' Chance of financial distress is determined by interpolating and adjusting InMed Altman Z Score to account for off-balance-sheet items and missing or unfiled public information. All items used in analyzing the odds of distress are taken from the InMed balance sheet, as well as cash flow and income statements available from the company's most recent filings. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in census.
InMed |
InMed Pharmaceuticals OTC Stock chance of financial distress Analysis
InMed Pharmaceuticals' Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current InMed Pharmaceuticals Probability Of Bankruptcy | Over 100% |
Most of InMed Pharmaceuticals' fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, InMed Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of InMed Pharmaceuticals probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting InMed Pharmaceuticals odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of InMed Pharmaceuticals financial health.
Please note, there is a significant difference between InMed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if InMed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, InMed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party. The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
CompetitionBased on the latest financial disclosure, InMed Pharmaceuticals has a Probability Of Bankruptcy of 100%. This is 131.0% higher than that of the Healthcare sector and 82.35% higher than that of the Biotechnology industry. The probability of bankruptcy for all United States stocks is 151.07% lower than that of the firm.
InMed Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses InMed Pharmaceuticals' direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of InMed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing InMed Pharmaceuticals by comparing valuation metrics of similar companies.InMed Pharmaceuticals is currently under evaluation in probability of bankruptcy category among related companies.
InMed Fundamentals
| Return On Equity | -91.74 | |||
| Return On Asset | -50.41 | |||
| Current Valuation | 35.74 M | |||
| Shares Outstanding | 158.2 K | |||
| Shares Owned By Insiders | 1.18 % | |||
| Shares Owned By Institutions | 0.09 % | |||
| Price To Earning | (11.11) X | |||
| Price To Book | 60.57 X | |||
| EBITDA | (7.19 M) | |||
| Net Income | (7.17 M) | |||
| Cash And Equivalents | 18.58 M | |||
| Cash Per Share | 0.11 X | |||
| Debt To Equity | 0.06 % | |||
| Current Ratio | 3.77 X | |||
| Book Value Per Share | 0.11 X | |||
| Cash Flow From Operations | (3.79 M) | |||
| Earnings Per Share | (0.05) X | |||
| Beta | 2.55 | |||
| Market Capitalization | 35.1 M | |||
| Total Asset | 1.21 M | |||
| Retained Earnings | (29.51 M) | |||
| Working Capital | (309 K) | |||
| Current Asset | 145 K | |||
| Current Liabilities | 454 K | |||
| Z Score | -50.1 |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards InMed Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, InMed Pharmaceuticals' short interest history, or implied volatility extrapolated from InMed Pharmaceuticals options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in census. Note that the InMed Pharmaceuticals information on this page should be used as a complementary analysis to other InMed Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in InMed OTC Stock
If you are still planning to invest in InMed Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the InMed Pharmaceuticals' history and understand the potential risks before investing.
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |